Acadia Pharmaceuticals (ACAD) Work In Process (2018 - 2026)

Acadia Pharmaceuticals' Work In Process history runs 9 years deep, the most recent figure standing at $80.7 million for Q1 2026.

• On a quarterly basis, Work In Process rose 0.87% year-over-year to $80.7 million in Q1 2026; TTM through Mar 2026 was $80.7 million, a 0.87% increase from a year earlier, with the FY2025 full-year figure at $76.7 million, up 9.98% from the prior year.
• Work In Process grew to $80.7 million in Q1 2026 per ACAD's latest filing, from $76.7 million in the prior quarter.
• Across five years, Work In Process topped out at $84.4 million in Q2 2025 and bottomed at $4.6 million in Q3 2023.
• The 5-year median for Work In Process is $6.2 million (2022), against an average of $32.8 million.
• Across the five-year window, Work In Process retreated 22.76% in 2023 and surged 1406.94% in 2024, its largest moves.
• Year by year, Work In Process stood at $4.9 million in 2022, then dropped by 6.01% to $4.6 million in 2023, then jumped by 1406.94% to $69.7 million in 2024, then advanced by 9.98% to $76.7 million in 2025, then increased by 5.23% to $80.7 million in 2026.
• Per Business Quant, the three latest ACAD Work In Process figures stand at $80.7 million (Q1 2026), $76.7 million (Q4 2025), and $76.9 million (Q3 2025).